Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Acquires $9,826,000.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Seamus Mulligan purchased 100,000 shares of the firm’s stock in a transaction that occurred on Friday, May 9th. The stock was acquired at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now owns 100,000 shares in the company, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Seamus Mulligan also recently made the following trade(s):

• On Monday, May 12th, Seamus Mulligan purchased 1,621 shares of Jazz Pharmaceuticals stock. The stock was acquired at an average price of $103.00 per share, with a total value of $166,963.00.

Jazz Pharmaceuticals Stock Down 0.6%

JAZZ opened at $102.91 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a 50 day moving average price of $118.23 and a 200-day moving average price of $122.25. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market capitalization of $6.34 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to analysts’ expectations of $984.16 million. During the same period in the previous year, the firm earned $2.68 earnings per share. The firm’s revenue for the quarter was down .5% on a year-over-year basis. Equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. Hurley Capital LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP increased its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. Finally, CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $28,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on JAZZ shares. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, HC Wainwright lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $182.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.